Objectives. HCQ, which is known to decrease SLE activity, may have a protective effect on survival, but this has not been proven in Asia. This study aimed to determine whether HCQ treatment is associated with increased survival in patients with SLE.
Introduction
SLE, a systemic autoimmune disease that primarily affects young females, is characterized by chronic inflammation and cumulative multiple organ damage that can be fatal. Despite the advent of earlier diagnosis and better treatment schedules, patients with SLE have a 2.6-fold higher standardized ratio of all-cause death compared with the general population [1, 2] . Infection, cardiovascular disease and end-organ damage remain the major causes of mortality in SLE [3] . Taiwanese SLE patients, especially those with juvenile-onset SLE, are also at increased risk of mortality [4] .
Immunosuppressive therapy to avoid repeated disease flares is essential in the treatment of SLE. Although multiple immunosuppressants have been developed, HCQ is still considered a cornerstone medication for this disease, both to control mild activity and as adjunctive therapy in cases of major organ involvement [5] . The safety of long-term HCQ therapy is acceptable in any period of life, even pregnancy [6] . HCQ reduces the risk of several conditions, including diabetes mellitus [7] , cancer [8] and dyslipidaemia [9] .
Some studies have shown enhanced survival with HCQ use in patients with SLE [1013] , possibly due to decreased SLE activity or multifaceted effects. However, these studies were conducted in Spain, the USA and Latin America. We questioned whether such a protective effect also appears by ethnicity, especially for Asian SLE patients, who are generally considered to have more severe disease activity [14] . The previous study provided insufficient information about whether the protective effect for survival was enhanced by HCQ adherence. Therefore, this prospective cohort study was designed with strict selection criteria and matching to determine whether long-term HCQ improves the survival of patients with SLE in Taiwan.
Methods

Study design and data source
This population-based cohort study retrieved data from the Taiwan National Health Insurance Research Database (NHIRD). Taiwan's National Health Insurance (NHI) system is a single-payer compulsory NHI scheme [15, 16] . The NHIRD comprehensively collects nationwide healthcare claim data on outpatient and inpatient services for >96% of Taiwan's population of 23 million individuals. The study was approved by the Chang Gung Medical Foundation Institutional Review Board (no. 201700328B1).
Inclusion eligibility
We screened a total of 23 366 patients with a diagnosis of SLE [International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) code 710.0] confirmed with a catastrophic illness certificate (CIC) between 1 January 2001 and 31 December 2013. SLE is classified as a catastrophic illness by the Ministry of Health and Welfare of Taiwan. After diagnosing a patient with SLE, a specialist can submit the CIC application on the patient's behalf. The NHI administration will assign another senior rheumatologist to anonymously review the application according to the 1997 ACR criteria for SLE [17] . We enrolled SLE subjects in the current study who had been issued CIC following the method described previously [8, 18] .
We included only new-onset SLE patients and those diagnosed before 1 January 2001 were excluded. The date of the CIC application for SLE was considered the index date. We also excluded patients with conditions that substantially affected survival, such as acute coronary syndrome, stroke, end-stage renal failure, liver cirrhosis, respiratory failure and malignancy, before the index date. Therefore, a total of 13 779 new-onset SLE patients with CIC were identified. Additionally, a 1-year follow-up quarantine period was required to estimate the HCQ exposure; patients with a follow-up duration <1 year or who died during the first year of follow-up were excluded (Fig. 1) .
HCQ exposure and adherence subgroups A total of 12 443 patients were ultimately eligible for the analysis and were divided into the HCQ and control groups according to the number of HCQ prescriptions as well as the daily prescribed dose. We defined the HCQ group (n = 10 078) as 'HCQ users' (>0 of 365 days) and the control group (n = 2365) as 'HCQ non-users' (0 of 365 days). After propensity score matching, each study group contained 2287 patients (Fig. 1) . The daily HCQ dose was 200400 mg in the study cohort.
The medication possession ratio (MPR) was defined as the ratio of doses available to a patient in a fixed period of time and was used to assess medication adherence [19] . The sum of the days' supply for all fills during the 1-year exposure period, including clinical visit prescription and refill prescription by the pharmacy, allowed us to analyse adherence using the MPR. The first-year MPR was defined as the MPR during the first 365 follow-up days. To determine whether different adherence levels resulted in different outcomes, we divided the patients into four subgroups: non-user, MPR <40%, 40% 4 MPR < 80% and MPR 580%, according to the first-year MPR of HCQ.
Covariate measurements
Comorbidities such as hypertension, diabetes mellitus, dyslipidaemia, gout, chronic kidney disease, coronary artery disease, peptic ulcer and chronic obstructive pulmonary disease had to be recorded twice as an outpatient diagnosis or once as a diagnosis with admission within 1 year before the index date using the ICD-9-CM diagnostic codes (supplementary Table S1 , available at Rheumatology online). Overlapping immune diseases, including SS and RA, were defined as the presence of the relevant ICD numbers in at least two records of an outpatient diagnosis or one diagnosis with admission during the first year after the index date. Medications such as aspirin, statins, warfarin, NSAIDs, systemic glucocorticoids, AZA, CYC and MTX had to be prescribed for at least 90 days during the first year. We also calculated prednisolone-equivalent glucocorticoid dose and recorded whether the patient used pulse steroid therapy during the first year. Medical care utilization related to SLE, such as the number of emergency room visits, number of admissions and number of hospitalization days due to SLE, was calculated during the first year.
Outcomes
The primary endpoint was mortality defined as withdrawal from the NHI [20] . The secondary endpoints were outcomes related to SLE activities including annual mean prednisolone-equivalent glucocorticoid dose, annual number of admissions and annual number of emergency room visits due to SLE. The follow-up period was based on the index date of the SLE diagnosis to the date of death or 31 December 2013, whichever came first.
Statistical analysis
To achieve comparability between the HCQ and control groups, we conducted propensity score matching to balance the baseline characteristics between the study groups. Each patient in the control group was matched to a counterpart in the HCQ group. The matching was processed using a greedy nearest neighbour algorithm with a caliper width 0.2 times the S.D. of the logit of the propensity score.
The characteristics of the patients in the HCQ and control groups were compared with a t-test for continuous variables or a Chi-square test for categorical variables. The incidence of mortality was reported as the event rate (proportion of events) and incidence density (number of events per 100 person-years). The risk of mortality between groups was compared using a Cox proportional hazard model. The association between mortality risk and HCQ adherence subgroups was investigated using a trend analysis of the log-rank test. The annual mean prednisolone-equivalent glucocorticoid dose was compared between the groups using a linear regression analysis in which the dose was log-transformed because of its non-normal distribution. The annual number of admissions (or emergency room visits) due to SLE was compared between groups using a Poisson regression model in which the logarithm of the follow-up duration was treated as the offset variable. The causes of death were compared between the HCQ and control groups using a Chi-square test. P < 0.05 were considered statistically significant. Data analyses were conducted using SAS software version 9.4 (SAS Institute, Cary, NC, USA).
Results
Study patients
In the cohort with a total of 12 443 patients, the mean (S.D.) age at SLE diagnosis was 35.4 (16.0) years. Women comprised 88.2% of the population. In the HCQ group (n = 10 078), the average number of days using HCQ in the first year was 278.5 (122.7) days and the mean daily dose was 333.8 mg. Table 1 shows the patient characteristics before and after propensity score matching. Before matching (Table 1 , left panel), the HCQ group had a lower prevalence of comorbidities (e.g. hypertension, diabetes mellitus, dyslipidaemia and chronic kidney disease), were more likely to be prescribed certain medications (e.g. aspirin, NSAIDs, systemic glucocorticoids, AZA, MTX) and less likely to be prescribed others (e.g. statins, CYC), used a lower cumulative glucocorticoid dose and had a higher prevalence of overlapping immune diseases (e.g. SS and RA) during the first year of follow-up. The HCQ group had a higher annual number of emergency room visits but a lower annual number of hospitalizations due to SLE during the first year of follow-up. We selected some variables, such as immunosuppressant use, cumulative glucocorticoid dose, pulse glucocorticoid therapy, medical care utilization of SLE and associated immune diseases, to function as proxies for SLE severity. The distribution of patient characteristics between the HCQ and control groups was comparable after matching (Table 1 , right panel).
Primary and secondary outcomes
During a mean (S.D.) follow-up of 7.6 (3.5) years, 169 (7.39%) and 248 (10.84%) patients died in the HCQ and control groups, respectively ( Table 2) . The proportion of all-cause mortality during follow-up is shown in Fig. 2 (Table 2) .
Subgroup analysis
Subgroup analyses of all-cause mortality were performed for the HCQ adherence subgroups, including HCQ non-users (n = 2365), MPR <40% (n = 1931), 40% 4 MPR < 80% (n = 2089) and MPR 580% (n = 6058). The mortality rate decreased significantly as adherence increased (P < 0.001 for trend) (Fig. 3) .
Further subgroup analyses of mortality were performed according to the following pre-specified subgroups: age group, sex, chronic kidney disease, AZA, CYC and pulse glucocorticoid therapy. The observed protective effect of HCQ was similar and comparable among the different subgroup levels (Fig. 4) .
Cause of death
We followed the method used in a previous study to define cause of death according to the principal hospitalization diagnosis in the 3 months preceding death [20] . The leading causes of death in our cohort were SLE activity (26.86%), infection (27.58%), malignancy (8.15%) and cardiovascular disease (7.91%). There was no significant difference in the proportion of causes of death between the HCQ and control groups (supplementary Table S2 , available at Rheumatology online). 
FIG. 2 Cumulative incidence rate of mortality
Discussion
This nationwide population-based study revealed that long-term HCQ improves survival, possibly due to the stabilizing of SLE activity, in patients with SLE compared with the control groups after propensity score matching. SLE patients administered HCQ also had decreased annual mean prednisolone-equivalent glucocorticoid doses, and annual numbers of hospital admissions and emergency room visits due to SLE compared with lupus patients not treated with HCQ. Using the subgroup analyses that accounted for the various HCQ adherence rates, we were able to estimate that a higher HCQ adherence provided a better survival benefit. These findings implied that HCQ not only decreases SLE activity but also improves survival with a dose-dependent effect. To our knowledge, only a few studies have examined the
FIG. 4 Subgroup analysis of mortality
FIG. 3 HCQ adherence subgroup analyses of mortality
association between survival and HCQ among patients with SLE, and this is the only one in Asia. The efficacy of HCQ in ameliorating the lipid profile and reducing incident diabetes mellitus and thrombovascular event risks, which have been convincingly demonstrated in previous studies [7, 21, 22] , may underlie the findings revealed in our study. Furthermore, the mechanism through which HCQ improves mortality has not been fully elucidated, but is most likely mediated via a reduction of flare severity [23] and end-organ damage [24] . HCQ might also decrease the requirement for immunosuppressants in SLE patients; thus, HCQ is considered to have a protective role against infection [25] . HCQ retinopathy is of concern during long-term therapy, but it remains uncommon and should not a reason for not prescribing HCQ for patients with SLE [26] .
HCQ has been reported to reduce SLE activity in two double-blind randomized clinical trials [27, 28] . In addition, continuing HCQ could protect patients with quiescent SLE from a clinical flare-up [23] . In our larger cohort study, we designated parameters associated with disease activity as secondary endpoints, including annual prednisoloneequivalent glucocorticoid dose, annual number of admissions due to SLE and annual number of emergency room visits due to SLE. Significant decreases in annual glucocorticoid doses and medical utilization were found in the HCQ group. Thus, we believe that our observation of survival improvement may have resulted from decreased disease activity in patients treated with HCQ, although this study regrettably could not directly assess SLE using a common index such as the SLEDAI or according to the BILAG criteria. A direct measurement of disease activity was not possible since linking the NHIRD to individual patients' laboratory results was forbidden for privacy reasons.
The survival of patients with SLE improved significantly with increasing adherence to HCQ as shown by a subgroup analysis. This is the first study to show an augmented effect on survival in SLE patients according to HCQ adherence (Fig. 3) . In the Grupo Latino Americano de Estudio del Lupus Eritematoso (GLADEL) cohort [12] , the relationship between HCQ exposure length and protection against mortality implied an effect due to adherence. One possible explanation is that patients with better adherence may lead better lifestyles, such as regular exercise, weight loss, smoking cessation and so on, which would result in better survival. Some patients would be prone to both recommendations, including higher medication adherence and lifestyle modification. For example, populations with higher education levels have better HCQ adherence [29] and are more likely to accept suggestions of smoking cessation [30] . Furthermore, HCQ might have a dose-dependent effect on SLE patient survival. Recent data also indicated that HCQ reduces the risk of diabetes mellitus and malignancy in SLE in a dose-dependent manner [6, 7] . However, future studies are needed to clarify whether a higher cumulative dose of HCQ also influences other parameters.
Because of the above benefits, we recommend the persistent use of HCQ for all SLE patients. In addition, we observed that 60% of our patients had good adherence to the HCQ treatment, defined as a first-year MPR 580%. Overall, the percentage of non-adherent patients was 4375% in the literature review and was higher in some vulnerable populations, including patients with depression, those from rural areas, with lower education levels and in polypharmacy [31] . A lack of sufficient adherence to HCQ is also associated with significantly higher subsequent acute care utilization and costs [32] . Therefore, we should be able to actively improve adherence by interventions such as providing education to raise awareness and organizing care with a nurse manager.
Because of the frequency with which physicians miss non-adherence as well as patient underreporting, it is never easy to evaluate actual adherence. Blood HCQ monitoring is useful in this setting [33] . Undetectable or unexpectedly low concentrations may be a simple, objective and reliable marker of non-adherence in SLE patients [34] . If such a concentration is detected in an unscheduled assay, the physician should have a nonjudgemental discussion with the patient to increase adherence. The scientific identification of non-adherence may prevent the misunderstanding of clinical manifestations as no response to therapy and avoid an unnecessary treatment escalation.
Further subgroup analyses of these relatively high lupus activity groups, including younger age, male sex, chronic kidney disease, AZA, CYC and pulse steroid therapy use, revealed no significant difference in the protective effect of survival on HCQ in all subgroups. The survival protective effect is universal and HCQ should be used in any specific subgroup. Our findings are compatible with the findings of a previous study which demonstrated that HCQ could decrease disease activity, even for pregnant women with SLE, and did not reveal additional congenital abnormalities [27] . We also analysed the cause of mortality of SLE and found major organ involvement and infection were the leading causes, followed by malignancy and cardiovascular events. Despite some discrepancies, our reports are identical to most results in Asia [14] . Between the HCQ and control groups, the distribution of mortality causes was similar in our cohort.
There are some strengths of this study, including its larger cohort (>10 000 patients) and longer follow-up period (mean 7.6 years) that those of previous studies, and the fact that we were able to examine the relationship between HCQ adherence and the survival protective effect. In addition, we used a prospective cohort design that could provide the precise HCQ exposure data and avoid an immortal time bias. To our knowledge, other than one Chinese study of LN [35] , this is the first report in Asia to prove the protective effect of HCQ on survival in patients with SLE. Compatible with previous reports in other regions [1013] , the protective effect is worldwide and not ethnicity-specific.
The current study also has some limitations. First, unmeasured and residual confounding variables are difficult to avoid in an observational study because there were no data of disease activity index or SLICC/ACR Damage Index information in the NHIRD. In the real world, treatment choice was dependent on the physician's judgement of the patient's clinical condition. Therefore, confounders that influenced treatment indication might bias the protective effect for survival attributed to HCQ. We made every endeavour to minimize the interference of this limitation by using propensity score matching. Apart from the general variables of age, sex, comorbidities and overlapping immune diseases, we matched the variables that would be associated with SLE activity, including cumulative glucocorticoid dose, immunosuppressants and medical healthcare utilization due to SLE, because the disease activity index was developed according to the principle of the physician's intention to treat. The strategy following the method designed for a previous study [36] might minimize the impact of residual confounding. However, we could not exclude the influence of SLICC/ACR Damage Index on mortality because of the unavoidable limitation of database studies. Only one NHIRD study [37] has attempted to match ICD-9-CM and procedure codes to the SLICC/ACR system. Nonetheless, higher estimates of the prevalence of some organ damage and the lack of a corresponding ICD-9-CM code in many manifestations were found. Only a prospective study, such as the GLADEL cohort [12] , could provide detailed information about the SLICC/ACR Damage Index. Second, although we designed a prospective study with a large cohort, this was not a randomized controlled trial. The data related to HCQ use after the first year of follow-up were not included. Moreover, even in the HCQ group, its use among participants was quite different. Therefore, we performed a further subgroup analysis to explore and identify the association between HCQ adherence and survival. A placebo-controlled randomized trial would be more appropriate for exploring the survival effect, but it may be unethical to deliberately group some SLE patients to not take HCQ, because of the good safety profile and other benefits of HCQ. Thus, our current study using the propensity score analysis to adjust for several important variables provided the most valuable evidence.
In conclusion, long-term HCQ therapy increases survival and decreases disease activity in patients with SLE, while the protective effect for survival might be associated with HCQ adherence. 
